These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2513445)

  • 1. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
    Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
    Huhtaniemi I; Nikula H; Rannikko S
    J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients].
    Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K
    Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
    Huhtaniemi I; Nikula H; Rannikko S; Clayton R
    J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer].
    Watanabe M; Fuji K; Suzuki K; Kitamura T; Okumura D; Kasahara T; Igarashi T; Masuyama T; Hiramori T; Higaki M; Yoshida H
    Nihon Hinyokika Gakkai Zasshi; 2003 Jul; 94(5):543-50. PubMed ID: 12910930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
    Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
    Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
    Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
    Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
    Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.